menu
    • menu
    [{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"OpenBench","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Tavros Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tavros Therapeutics \/ Tavros Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Tavros Therapeutics \/ Tavros Therapeutics"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Tavros Therapeutics

    Menu

    Tavros Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tavros Therapeutics

                            U.S.A arrow
                            Pharma Europe
                            Not Confirmed

                            Tavros Therapeutics

                            U.S.A arrow
                            Pharma Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Vividion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Vividion Acquires Tavros to Enhance Functional Genomics Drug Discovery

                            Details : Through the acquisition, Vividion will utilize Tavros Therapeutics' precision oncology platform to focus on developing promising drug targets for cancer treatment.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Vividion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tavros Therapeutics

                            U.S.A arrow
                            Pharma Europe
                            Not Confirmed

                            Tavros Therapeutics

                            U.S.A arrow
                            Pharma Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Vividion Therapeutics

                            Deal Size : $448.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tavros Therapeutics Achieves Two Milestone Payments in Collaboration with Vividion

                            Details : The collaboration aims to deliver novel precision therapeutics capable of addressing cancer-causing proteins that have eluded traditional small molecule drugs.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : $17.5 million

                            May 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Vividion Therapeutics

                            Deal Size : $448.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tavros Therapeutics

                            U.S.A arrow
                            Pharma Europe
                            Not Confirmed

                            Tavros Therapeutics

                            U.S.A arrow
                            Pharma Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : OpenBench

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery

                            Details : The multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s AI-enabled screening platform to discover small molecule modulators of up to five oncology targets across an initial 18-month term.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 27, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : OpenBench

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tavros Therapeutics

                            U.S.A arrow
                            Pharma Europe
                            Not Confirmed

                            Tavros Therapeutics

                            U.S.A arrow
                            Pharma Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Vividion Therapeutics

                            Deal Size : $448.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targete...

                            Details : Tavros leverages its functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need and identify novel clinical positioning strategies for e...

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : $17.5 million

                            October 12, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Vividion Therapeutics

                            Deal Size : $448.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth